Viral Inactivation Market size in 2019 is estimated to be $450 million, growing at a CAGR of 12% during the forecast period 2020-2025. Viral inactivation is a method of viral removal process in which the viruses may remain in the final product, but in a non-infective form. Viral inactivation is an important part of the viral clearance process. The Virus inactivation process is a critical step in process development for biologicals such as tissue and tissue products, stem cell products, and vaccines and therapeutics. Increasing number of chronic disease and technological advancement are the major factors driving the growth of the market. Moreover, increasing R&D innovation and increasing healthcare expenditure further enhance the overall market demand for viral inactivation during the forecast period 2020-2025.
The report: “Viral Inactivation Market – Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Viral Inactivation Market:
By Method: Solvent Detergent Method, Pasteurization, pH Concentration method, Alkylating agent method, Radiation method, and Others
By Product: Kits & Reagents, Services, Viral Inactivation Systems & Accessories
By Application: Vaccines & Therapeutics, Blood & Blood Products, Cellular & Gene Therapy Products, Tissues & Tissue Products, Stem Cell Products, and Others
By End-Use: Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, and Others
By Geography: North America, Europe, Asia-Pacific, and Rest of the World
- In 2019, North America dominates the viral inactivation market owing to advanced healthcare infrastructure, advanced instruments and technologies and increasing healthcare expenditure.
- Increasing number of chronic diseases and technological advancement is driving the market growth of viral inactivation.
- Detailed analysis of the Strength, Weakness, and opportunities of the prominent players operating in the market will be provided in the viral inactivation market report.
- Highly expensive manufacturing process of biosimilars are challenging the growth of the market.
Application - Segment Analysis
Based on the Application, Viral Inactivation Market is segmented into Vaccines & Therapeutics, Blood & Blood Products, Cellular & Gene Therapy Products, Tissues & Tissue Products, Stem Cell Products, and Others. Vaccines & Therapeutics segment is forecast to be the fastest-growing segment and is estimated to grow at a CAGR of 9.3% during the forecast period 2020-2025. This is mainly owing to growth in biologics production and increase in government funding for the promotion of usage of biologics to treat disease. Moreover, Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim to treat late stage disease by using a patient's own immune system that are contributing the growth of this segment.
End-Use - Segment Analysis
Based on the End-Use, Viral Inactivation Market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, and Others. In 2019, pharmaceutical & biotechnology companies held the largest share in the viral inactivation market. This is mainly owing to increased usage of these products for the purpose of drug development and drug manufacturing that are contributing to the growth of this segment.
Geography - Segment Analysis
North America dominated the viral inactivation market share accounting for 42% of the market in 2019. This is mainly owing to advanced healthcare infrastructure, advanced instruments and technologies and increasing healthcare expenditure. According to U.S. Food and Drug Association, vital inactivation has been made mandatory step for investigation of new drugs in the view of safety concerns that are contributing the growth of this market.
However, the Asia-Pacific region is forecast to be the fastest-growing during the forecast period 2020-2025. This is owing to the growth in healthcare infrastructure and rising awareness among people about disease.
Drivers – Viral Inactivation Market
- Increasing number of chronic diseases
Increasing number of chronic diseases such as cancer, diabetes, autoimmune disorders, and other diseases awareness among patients are some factors driving the growth of viral inactivation market. Moreover, increase investment in the life science sector and increase in R&D innovation are also set to increase the market growth.
- Technological Advancements
Technological Advancements, increasing drug launches & approval and increasing healthcare expenditure are some factors driving the growth of the market. Moreover, technological evolution in the medical industry increasing the demand for viral inactivation process and developing new & enhanced therapies to tackle the rise in many diseases and increasing drug discoveries further contributing the growth of viral inactivation market.
Challenges – Viral Inactivation Market
Highly expensive manufacturing process of biosimilars are challenging the growth of the market. Moreover, some problems associated with the virus inactivation process such as virus aggregate formulation, protein crosslinking and protein denaturation and degradation are further restraining its market growth during the forecast period 2020-2025.
Viral Inactivation Industry Outlook
Product launches, Merger & Acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Viral Inactivation Market. Viral Inactivation top 10 companies are Merck KGaA, Danaher corporation, Sartorius AG, Charles River, SGS SA, PARKER HANNIFIN CORP, Clean Cells, Rad Source Technologies, Texcell and WuXi AppTec.
- On 27 September 2019, Merck KGaA has acquisition with Pfizer Inc. and launches new drug BAVENCIO for the removal of virus and also helps to treat many diseases such as cancers including, renal cell carcinoma, metastatic and many more.
- On 1 March 2019, Clean Cells has acquisition with NAOBiOS for the development of viral vaccines and used for the treatment of many diseases.
1. Viral Inactivation Market Overview
1.1 Definitions and Scope
2. Viral Inactivation Market- Executive Summary
2.1 Market Revenue, Market Size and Key Trends by Company
2.2 Key trends by Method
2.3 Key trends by Product
2.4 Key trends by Application
2.5 Key trends by End-Use
2.6 Key trends by Geography
3. Viral Inactivation Market Landscape
3.1 Market Share Analysis- Key Companies
3.2 Product Benchmarking- Key Companies
3.3 Financial Analysis - Key Companies
3.4 Patent Analysis - Key Companies
3.5 Pricing Analysis
4. Viral Inactivation Market- Startup companies Scenario Premium (Premium)
4.1 Key startup company Analysis by
4.1.3 Application Analysis
4.1.4 Venture Capital and Funding Scenario
5. Viral Inactivation Market - Industry Market Entry Scenario Premium (Premium)
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case Studies of successful ventures
6. Viral Inactivation Market Forces
6.1 Market Drivers
6.2 Market Constraints/Challenges
6.3 Porters Five Force Model
6.3.1 Bargaining Power of Suppliers
6.3.2 Bargaining Powers of Customers
6.3.3 Threat of New Entrants
6.3.4 Rivalry Among Existing Players
6.3.5 Threat of Substitutes
7. Viral Inactivation Market - Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle
8. Viral Inactivation Market – By Method (Market Size -$Million/$Billion)
8.1 Solvent Detergent Method
8.3 pH Concentration method
8.4 Alkylating agent method
8.5 Radiation method
9. Viral Inactivation Market – By Product (Market Size -$Million/$Billion)
9.1 Kits & Reagents
9.3 Viral Inactivation Systems & Accessories
10. Viral Inactivation Market – By Application (Market Size -$Million/$Billion)
10.1 Vaccines & Therapeutics
10.2 Blood & Blood Products
10.3 Cellular & Gene Therapy Products
10.4 Tissues & Tissue Products
10.5 Stem Cell Products
11. Viral Inactivation Market – By End-Use (Market Size -$Million/$Billion)
11.1 Pharmaceutical & Biotechnology Companies
11.2 Contract Research Organizations
11.3 Academic Research Institutes
12. Viral Inactivation Market - By Geography (Market Size -$Million/$Billion)
12.1 North America
12.2.6 Rest of Europe
12.3.3 South Korea
12.3.5 Australia & New Zealand
12.3.6 Rest of Asia-Pacific
12.4 Rest of the World
12.4.1 Middle East
12.4.3 South America
13. Viral Inactivation Market – Entropy
14. Viral Inactivation Market Industry / Segment Competition landscape Premium (Premium)
14.1 Market Share Analysis
14.1.1 Market Share by Country- Key companies
14.1.2 Market Share by Region- Key companies
14.1.3 Market Share at Global Level- Key companies
14.1.4 Best Practices for Companies
15. Viral Inactivation Market - Key Company List by Country Premium (Premium)
16. Viral Inactivation Market Company Analysis
16.1 Company Revenue, Products, M&A, Developments
16.2 Company 1
16.3 Company 2
16.4 Company 3
16.5 Company 4
16.6 Company 5
16.7 Company 6
16.8 Company 7
16.9 Company 8
16.10 Company 9
16.11 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.